An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Beta blockers were associated with later appearance of motor symptoms and slower symptom worsening, but an outside expert ...